Dr. Ferris on the Safety Profile for RTOG 3504 for Head and Neck Cancer

Robert Ferris, MD, PhD
Published: Friday, Jun 23, 2017



Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the safety profile of the RTOG 3504 trial for patients with head and neck cancer

For the RTOG 3504 trial, the phase I component is still ongoing. According to Ferris, it would be a surprise if there was a dose-limiting toxicity, partly because there are some investigator sponsored trials with both nivolumab (Opdivo) and pembrolizumab (Keytruda), which released safety data.
 


Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the safety profile of the RTOG 3504 trial for patients with head and neck cancer

For the RTOG 3504 trial, the phase I component is still ongoing. According to Ferris, it would be a surprise if there was a dose-limiting toxicity, partly because there are some investigator sponsored trials with both nivolumab (Opdivo) and pembrolizumab (Keytruda), which released safety data.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x